logo
What Trump's 30% tariff threat means for the European Union — in charts

What Trump's 30% tariff threat means for the European Union — in charts

CNBCa day ago
U.S. President Donald Trump has pledged to impose a 30% tariff on imports from the European Union from August 1. The announcement, which follows similar warnings to other trading partners, could make everything from German machinery and French cheese to Italian luxury goods and Danish pharmaceuticals more expensive in the U.S. Trump revealed the new rate in a letter to European Commission President Ursula von der Leyen, which he posted on Saturday on his social media site Truth Social. The U.S. president shared a similar letter to Mexican President Claudia Sheinbaum. For the EU, the prospect of fresh U.S. tariffs represents a major blow. The 27-nation bloc had been scrambling to secure a preliminary agreement to spare it from becoming the latest recipient of a Trump letter dictating a new, across-the-board tariff on its exports to the U.S. Here's a look at some of the key figures of the U.S.-EU's massive trading relationship. The U.S. and EU have the largest bilateral trade and investment relationship in the world, representing almost 30% of global trade in goods and services, and accounting for 43% of global gross domestic product (GDP), according to EU figures . Last year alone, the value of EU-U.S. trade amounted to 1.68 trillion euros ($1.96 trillion). That's the equivalent of roughly 4.6 billion euros of trade per day. Trump has repeatedly hit out at the EU for what he perceives to be an unfair trading relationship, often citing the EU's trade surplus with the U.S. For its part, the EU has signaled a willingness to reduce its 198 billion euros trade surplus in goods with the U.S. by increasing its purchase of U.S. products, notably defense and liquified natural gas (LNG). Taking into account both trade and services, the EU's total trade surplus with the U.S. stood at a total of 50 billion euros in 2024, a figure which the bloc says represents less than 3% of total U.S.-EU trade. By sector, the pharmaceutical, automotive and aircraft sectors appear to be the most exposed to U.S. tariffs, while Germany, Italy and Ireland are among the EU members likely to be the hardest hit. Trump has said the proposed 30% tariff rate would be separate from sectoral tariffs, suggesting the 50% duties on steel and aluminum imports and 25% on auto imports would remain. The EU has not yet retaliated to Trump's next big tariff deadline. EU ministers are meeting in Brussels, Belgium on Monday to discuss how best to respond. In a Monday note, analysts at UBS said they continued to believe the EU and U.S. would reach an agreement before Aug. 1 or that the White House would extend its deadline again while negotiations continue. However, they added that "aggressive" U.S. demands, including for complete open market access with no tariff charged to it, made it hard to predict how Brussels would respond and increased the risk of economic damage to both sides. — CNBC's Jenni Reid contributed to this report.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

US inflation accelerated in June as Trump's tariffs start to bite
US inflation accelerated in June as Trump's tariffs start to bite

Chicago Tribune

time15 minutes ago

  • Chicago Tribune

US inflation accelerated in June as Trump's tariffs start to bite

WASHINGTON — Inflation rose last month to its highest level since February as President Donald Trump's sweeping tariffs are pushing up the cost of a range of goods, including furniture, clothing, and large appliances. Consumer prices rose 2.7% in June from a year earlier, the Labor Department said Tuesday, up from an annual increase of 2.4% in May. On a monthly basis, prices climbed 0.3% from May to June, after rising just 0.1% the previous month. Worsening inflation poses a political challenge for President Donald Trump, who promised during last year's presidential campaign to immediately lower costs. The sharp inflation spike of 2022-2023 was the worst in four decades and soured most Americans on former president Joe Biden's handling of the economy. Higher inflation will also likely heighten the Federal Reserve's reluctance to cut its short-term interest rate, as Trump is loudly demanding. Trump has often insisted in comments on social media that there is 'no inflation' and that as a result, the central bank should swiftly reduce its key interest rate from its current level of 4.3% to around 3%. Excluding the volatile food and energy categories, core inflation increased 2.9% in June from a year earlier, up from 2.8% in May. On a monthly basis, it picked up 0.2% from May to June. Economists closely watch core prices because they typically provide a better sense of where inflation is headed. The uptick in inflation was driven by a range of higher prices. The cost of gas rose 1% just from May to June, while grocery prices increased 0.35. Appliance prices jumped for the third straight month. Trump has imposed sweeping duties of 10% on all imports, plus 50% levies on steel and aluminum, 30% on goods from China, and 25% on imported cars. Just last week the president threatened to hit the European Union with a new 30% tariff starting Aug. 1. The acceleration in inflation could provide a respite of sorts for Federal Reserve Chair Jerome Powell, who has come under increasingly heavy fire from the White House for not cutting the benchmark interest rate. Powell and other Fed officials have emphasized that they want to see how the economy evolves as the tariffs take effect before cutting their key short-term rate. The Fed chair has said that the duties could both push up prices and slow the economy, a tricky combination for the central bank since higher costs would typically lead the Fed to hike rates while a weaker economy often spurs it to reduce them. Trump on Monday said that Powell has been 'terrible' and 'doesn't know what the hell he's doing.' The president added that the economy was doing well despite Powell's refusal to reduce rates, but it would be 'nice' if there were rate cuts 'because people would be able to buy housing a lot easier.' Last week, White House officials also attacked Powell for cost overruns on the years-long renovation of two Fed buildings, which are now slated to cost $2.5 billion, roughly one-third more than originally budgeted. While Trump legally can't fire Powell just because he disagrees with his interest rate decisions, the Supreme Court has signaled, he may be able to do so 'for cause,' such as misconduct or mismanagement. Some companies have said they have or plan to raise prices as a result of the tariffs, including Walmart, the world's largest retailer. Automaker Mitsubishi said last month that it was lifting prices by an average of 2.1% in response to the duties, and Nike has said it would implement 'surgical' price hikes to offset tariff costs. But many companies have been able to postpone or avoid price increases, after building up their stockpiles of goods this spring to get ahead of the duties. Other companies may have refrained from lifting prices while they wait to see whether the U.S. is able to reach trade deals with other countries that lower the duties.

LEO Pharma secures rights to Boehringer's Spevigo for $105m
LEO Pharma secures rights to Boehringer's Spevigo for $105m

Yahoo

time15 minutes ago

  • Yahoo

LEO Pharma secures rights to Boehringer's Spevigo for $105m

Danish dermatology leader LEO Pharma has bought the rights to Boehringer Ingelheim's psoriasis drug Spevigo (spesolimab) for €90m ($105m), strengthening its portfolio ahead of a possible public listing in 2026. The transaction will see LEO gain the exclusive global licence for Spevigo, taking control of commercialisation and development rights. The full terms of the deal were not disclosed as both companies are privately owned, but LEO confirmed it is in line for milestone payments and royalties. The deal is expected to close in the second half of 2025. Spevigo is approved in the US, Japan, China and most European countries to treat generalised pustular psoriasis (GPP) flares, a rare but severe dermatological disease that can be fatal. It has also been approved in expanded indications in GPP in certain territories. LEO's new asset is a monoclonal antibody that blocks the activation of the interleukin-36 (IL-36) receptor - a key signalling pathway in the immune system implicated in the pathogenesis of several autoinflammatory diseases. Indeed, GPP may not be the ceiling for Spevigo – LEO said there is an 'opportunity to investigate the potential of Spevigo in additional skin conditions with high unmet medical need in which IL-36 is implicated'. LEO calls Spevigo 'the flagship dermatology product' of Boehringer Ingelheim, though the drug's sales have not been publicly disclosed. Comparing sales from other drugs is tricky because Spevigo is the only US Food and Drug Administration (FDA)-approved treatment specifically for GPP. Boehringer Ingelheim's head of human pharma Shashank Deshpande said: 'Spevigo holds a significant promise, and ensuring it reaches its full potential requires continued focus and expertise in medical dermatology. With over six decades of singular dedication to this field, LEO Pharma is exceptionally well-positioned to build on the strong foundation we've laid.' Adding Spevigo to its portfolio represents a strengthening of assets for dermatology specialist LEO. The Danish drugmaker has been building its pipeline amid reports it is planning an initial public offering (IPO) next year. Christophe Bourdon, who was appointed CEO in 2022 and tasked with turning the fortunes of the company around, has made no secret of public listing plans. In an interview with Bloomberg yesterday [14 July], Bourdon said market conditions and shareholders' wishes will decide the best timing for an IPO. The deal with Boehringer Ingelheim marks the second time LEO has signed a licensing agreement with a big pharma company in 2025. In January, Gilead Sciences offered a potential $1.7bn for LEO's preclinical STAT6 research programmes, which the dermatology company agreed to. As part of the deal, LEO received $250m in an upfront payment, boosting its cash on hand. "LEO Pharma secures rights to Boehringer's Spevigo for $105m" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio

Canada's inflation rate heats up in June
Canada's inflation rate heats up in June

Yahoo

time16 minutes ago

  • Yahoo

Canada's inflation rate heats up in June

Canada's inflation rate accelerated to 1.9 per cent in June, up from 1.7 per cent the previous month, as disruptions to North American trade started to have an impact on consumer prices. Prices increased in seven major components of the consumer price index basket, while gasoline prices fell to a lesser extent than in May, driving the overall rise in inflation, Statistics Canada said on Tuesday. Excluding energy, the consumer price index rose by 2.7 per cent in June. Tuesday's inflation reading is the last major economic data release before the Bank of Canada's next interest rate decision on July 30. Core inflation, the measures the central bank prefers to look at when making its monetary policy decisions, also remained elevated near three per cent. Five questions about Trump's 35% tariff threat to Canada Bank of Canada rate cut in July looks less likely on surprise job gains More to come … Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store